A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)

Trial Profile

A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 19 Dec 2017 According to a VBI Vaccines media release, based on the results of this trail and other phase III trial (286793), company expects to submit marketing authorization applications to U.S., European, and Canadian regulatory authorities in 2019. Also, Dr. Nathan Segall, is a Principal Investigator of this phase 3 program.
    • 18 Dec 2017 Status changed from planning to recruiting, According to a VBI Vaccines media release.
    • 30 Aug 2017 According to a VBI Vaccines media release, the company expects to initiate in the second half of 2017 in the U.S., Europe and Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top